The Absolute Effect / Oncology Evidence / Evidence Index
GOG-0213
In selected platinum-sensitive recurrent ovarian cancer, does secondary cytoreductive surgery before chemotherapy improve overall survival compared with chemotherapy alone?
Registry: NCT00565851 · Evidence reviewed 9 November 2026 · Aliases and follow-up publications consolidated.
Phase III randomized; n=485.Primary-source evidence summaryStudy design, population and eligibility
Phase III randomized; n=485.
Platinum-sensitive recurrence selected for potential complete gross resection; most received platinum chemo and bevacizumab.
Treatment and comparator
Intervention: Secondary cytoreduction then chemotherapy.
Comparator: Chemotherapy without surgery.
Endpoints
OS primary.
Key efficacy and clinical outcomes
Median OS 50.6 mo surgery vs 64.7 mo no surgery (HR 1.29; p=.08); PFS 18.9 vs 16.2 mo (HR .82).
Source-reported outcome visualization
Values are reproduced from the cited report; bars are scaled within this figure. Platinum-sensitive recurrent ovarian/fallopian tube/primary peritoneal cancer
Median survival and hazard ratios are not fixed-time event risks; NNT is not inferred from them.
Toxicity and treatment burden
30-day surgical morbidity 9%; postoperative death 0.4%; temporary QoL decline.
Absolute effect and NNT/NNH
Primary OS endpoint negative. DESKTOP III differs in selection criteria; selection for complete resection matters.
NNT/NNH is not calculated unless a directly reported, comparable fixed-time risk difference supports it. Median survival and hazard ratios alone do not provide an NNT.
Critical interpretation and limitations
Primary OS endpoint negative. DESKTOP III differs in selection criteria; selection for complete resection matters.
This page is an evidence summary, not a substitute for multidisciplinary assessment or patient-specific decision-making.
Current-practice context
Review date: 9 November 2026. Primary publication and selected follow-up sources were reviewed. Full disease-specific guideline, regulatory-label and sequencing audit remains pending; verify current local recommendations and biomarker eligibility before clinical application.